Lymphoma, Primary Effusion
1 clinical trials · Condition
◉ Watch Lymphoma, Primary Effusion
| Record | Firm | Date |
|---|---|---|
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease (NCT05907759) | National Cancer Institute (NCI) | 2024-07-10 |
Track Lymphoma, Primary Effusion automatically
Every clearance here is in the API, with alerts when new ones post.